BRPI1011925A2 - método de diagnóstico para previsão do risco de recorrência de câncer com base em isoformas de histona macroh2a - Google Patents

método de diagnóstico para previsão do risco de recorrência de câncer com base em isoformas de histona macroh2a

Info

Publication number
BRPI1011925A2
BRPI1011925A2 BRPI1011925A BRPI1011925A BRPI1011925A2 BR PI1011925 A2 BRPI1011925 A2 BR PI1011925A2 BR PI1011925 A BRPI1011925 A BR PI1011925A BR PI1011925 A BRPI1011925 A BR PI1011925A BR PI1011925 A2 BRPI1011925 A2 BR PI1011925A2
Authority
BR
Brazil
Prior art keywords
macroh2a
diagnostic method
cancer recurrence
risk based
recurrence risk
Prior art date
Application number
BRPI1011925A
Other languages
English (en)
Portuguese (pt)
Inventor
Ladurner Andreas
Sporn Judith
Muley Thomas
Original Assignee
Embl European Molecular Biology Laboratory
Thoraxklinik Heidelberg Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Embl European Molecular Biology Laboratory, Thoraxklinik Heidelberg Gmbh filed Critical Embl European Molecular Biology Laboratory
Publication of BRPI1011925A2 publication Critical patent/BRPI1011925A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI1011925A 2009-07-02 2010-07-02 método de diagnóstico para previsão do risco de recorrência de câncer com base em isoformas de histona macroh2a BRPI1011925A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09008679A EP2270510A1 (en) 2009-07-02 2009-07-02 Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
PCT/EP2010/004008 WO2011000573A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Publications (1)

Publication Number Publication Date
BRPI1011925A2 true BRPI1011925A2 (pt) 2017-10-10

Family

ID=41100520

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011925A BRPI1011925A2 (pt) 2009-07-02 2010-07-02 método de diagnóstico para previsão do risco de recorrência de câncer com base em isoformas de histona macroh2a

Country Status (11)

Country Link
US (1) US20120171225A1 (enExample)
EP (2) EP2270510A1 (enExample)
JP (1) JP5792165B2 (enExample)
CN (1) CN102472753B (enExample)
AU (1) AU2010268389B2 (enExample)
BR (1) BRPI1011925A2 (enExample)
CA (1) CA2766656A1 (enExample)
ES (1) ES2681687T3 (enExample)
SG (1) SG177398A1 (enExample)
WO (1) WO2011000573A1 (enExample)
ZA (1) ZA201109381B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
EP3546944A1 (en) * 2018-03-30 2019-10-02 Universite d'Aix-Marseille (AMU) Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
CN119736252B (zh) * 2025-01-15 2025-06-27 首都医科大学 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
EP1388734B1 (en) * 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20050085628A1 (en) * 2002-01-31 2005-04-21 Kinya Yoda Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same
CN100480382C (zh) * 2002-08-16 2009-04-22 抗癌公司 实时测量细胞反应
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2004106511A1 (ja) * 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
EP1682904A2 (en) * 2003-11-04 2006-07-26 Roche Diagnostics GmbH Method for distinguishing who classified aml subtypes
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006119435A2 (en) * 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US9150628B2 (en) * 2005-11-14 2015-10-06 Centre National De La Recherche Scientifique (Cnrs) PARP inhibitors
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2008292424A (ja) * 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
BRPI0815460A2 (pt) * 2007-09-07 2019-02-26 Univ Bruxelles kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos
CA2726531A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Also Published As

Publication number Publication date
JP2012531612A (ja) 2012-12-10
US20120171225A1 (en) 2012-07-05
EP2449383B1 (en) 2018-05-16
AU2010268389A1 (en) 2012-01-19
EP2270510A1 (en) 2011-01-05
AU2010268389A2 (en) 2012-01-12
WO2011000573A1 (en) 2011-01-06
SG177398A1 (en) 2012-02-28
ZA201109381B (en) 2012-08-29
EP2449383A1 (en) 2012-05-09
AU2010268389B2 (en) 2014-09-11
CA2766656A1 (en) 2011-01-06
ES2681687T3 (es) 2018-09-14
CN102472753B (zh) 2015-02-11
JP5792165B2 (ja) 2015-10-07
CN102472753A (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
BRPI0913924A2 (pt) métodos e sistemas para avaliação de infertilidade clínica
BRPI0919064A2 (pt) estação de acoplamento com mecanismo de rotação
BR112012001315A2 (pt) técnicas para análise de energia
BR112013012037A2 (pt) sistemas, métodos e/ou aparelhos para geração de energia termoelétrica
BR112014000451A2 (pt) sistemas e métodos para determinar coberturas opcionais de seguro
BRPI0722200A2 (pt) Método para calibração de setores
BRPI1014827A2 (pt) mecanismo de carregamento automatizado para aparelhos de detecção microbiana
BRPI0910412A2 (pt) sistemas e metodologia para distribuição de energia
BRPI0920218A2 (pt) aparelho de mamografia e método para rastreamento da ocorrência de células malignas
BRPI0815725A2 (pt) Métodos para detecção de oligonucleotídeos
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
BRPI0914310A2 (pt) sistemas, aparelhos, e métodos para prover eletroterapia não transcraniana
BRPI0817378A2 (pt) Conjunto sensor para um barramento de energia
PL2653546T3 (pl) Marker do ustalenia rokowania raka żołądka i sposób ustalenia rokowania raka żołądka
BR112012002604A2 (pt) sistemas e métodos para entrega de anúncios direcionada
BRPI1006075A2 (pt) biomarcadores de cancer
BRPI1011925A2 (pt) método de diagnóstico para previsão do risco de recorrência de câncer com base em isoformas de histona macroh2a
BRPI0908003A2 (pt) sistemas e métodos para o envio de terapia de radiação
BRPI1015922A2 (pt) sistemas e métodos para testar analitos
EP2625292A4 (en) KREBSBIOMARKER
PT3985979T (pt) Método e dispositivo para determinação de unidade de referência
BRPI1011788A2 (pt) método e aparelho para tomografia de imagem de resistividade de perfilagem de poço
BRPI1012528A2 (pt) aparelho para depósito
BRPI1011686A2 (pt) método para economia de energia em um ponto de acesso
BRPI1011246A2 (pt) métodos e aparelho para gerenciamento de trasferência móvel

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements